thalidomide has been researched along with Bile Duct Cancer in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using our rat cholangiocarcinoma model, we demonstrated that thalidomide inhibited tumor growth and was associated with a decrease in expression of reduced eIF4E and VEGF expression; in addition, thalidomide preserved fast-twitch skeletal muscle fibers and was associated with decreased expression of TNFalpha and TGFbeta1." | 7.74 | Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats. ( Liao, LM; Liu, KH; Ro, LS; Wu, YL; Yeh, TS, 2008) |
| "Using our rat cholangiocarcinoma model, we demonstrated that thalidomide inhibited tumor growth and was associated with a decrease in expression of reduced eIF4E and VEGF expression; in addition, thalidomide preserved fast-twitch skeletal muscle fibers and was associated with decreased expression of TNFalpha and TGFbeta1." | 3.74 | Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats. ( Liao, LM; Liu, KH; Ro, LS; Wu, YL; Yeh, TS, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mizutani, S | 1 |
| Kuroda, J | 1 |
| Sasaki, N | 1 |
| Kiyota, M | 1 |
| Tatekawa, S | 1 |
| Tsukamoto, T | 1 |
| Maegawa, S | 1 |
| Chinen, Y | 1 |
| Shimura, Y | 1 |
| Nagoshi, H | 1 |
| Kobayashi, T | 1 |
| Horiike, S | 1 |
| Tando, S | 1 |
| Fushiki, S | 1 |
| Taniwaki, M | 1 |
| Liu, KH | 1 |
| Liao, LM | 1 |
| Ro, LS | 1 |
| Wu, YL | 1 |
| Yeh, TS | 1 |
2 other studies available for thalidomide and Bile Duct Cancer
| Article | Year |
|---|---|
Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers.
Topics: Aged; Bile Duct Neoplasms; Bortezomib; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; C | 2016 |
Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cachexia | 2008 |